Skip to main content

Recombinant Human Integrin alpha X beta 2 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 5755-AX

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
5755-AX-050

Key Product Details

Source

CHO

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human Integrin alpha X beta 2 protein
Human Integrin alphaX
(Phe20-Pro1107)
Accession # P20702
Acidic Tail 6-His tag
Human Integrin beta2
(Gln23-Asn700)
Accession # AAA59490
Basic Tail
N-terminus C-terminus

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe20 ( alphaX) & Gln23: predicted, no results obtained ( beta2)

Predicted Molecular Mass

128.9 kDa ( alphaX) & 83.1 kDa ( beta2)

SDS-PAGE

149 kDa & 103 kDa, reducing conditions

Activity

Measured by the ability of the immobilized protein to support adhesion of J45.01 human acute lymphoblastic leukemia T lymphocytes.
When 5 x 104 cells are added to Recombinant Human Integrin  alphaX beta2 coated plates (10 μg/mL, 100 μL/well), more than 50% will adhere after 1 hour at 37 °C.

Formulation, Preparation and Storage

5755-AX
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Integrin alpha X beta 2

Integrin alphaX beta2, also called CD11c/CD18, p150/95 or complement receptor type 4 (CR4), is one of four beta2 integrins. The non-covalent heterodimer of 150 kDa alphaX/CD11c and 95 kDa beta2/CD18 integrin subunits is expressed on macrophages, dendritic cells and hairy cell leukemias, with lower amounts on other myeloid cells and activated B, NK and some cytotoxic T cells (1‑7). Like other integrins, alphaX beta2 has multiple activation states (3). In the presence of divalent cations and "inside-out" signaling, alphaX beta2 is fully active and extended. The alphaX vWFA or I-domain, which contains the adhesion sites, forms the N-terminal head region with the alphaX beta-propeller and the beta2 vWFA domain (1, 8). In the inactive state, the heterodimer flexes in the center at the alphaX thigh and calf domains and beta2 I-EGF domains, impeding access to adhesion sites (1). The 1088 aa human alphaX/CD11c ECD shares 70‑76% aa sequence identity with mouse, rat and canine alphaX while the 678 aa human beta2/CD18 ECD shares 81‑83% aa sequence identity with mouse, rat, cow, dog, goat, sheep, and pig beta2. Potential alphaX isoforms containing 719 and 725 aa (as compared to full-length 1163 aa alphaX) lack the vWFA domain and the N-terminus. Active alphaX beta2 shares some adhesion partners with alphaM beta2/CD11b/CD18, including complement opsonin fragment iC3b, ICAMs, vWF and fibrinogen, and is expressed on many of the same cells (4‑11). However, alphaM beta2 activity is often constitutive, while alphaX beta2 activity requires cell activation (4‑7). alphaX beta2 also binds osteopontin, Thy-1, plasminogen, heparin, and proteins with abnormally exposed acidic residues (11‑16). The adhesion events are important for proliferation, degranulation, chemotactic migration, and phagocytosis of complement-opsonized particles (5, 6, 9, 11, 12, 16). Mutations of beta2, especially in the vWFA domain, cause leukocyte adhesion deficiency (LAD-1) and susceptibility to bacterial infections (17).

References

  1. Corbi, A.L. et al. (1987) EMBO J. 6:4023.
  2. Kishimoto, T.K. et al. (1987) Cell 48:681.
  3. Hynes, R.O. (2002) Cell 110:673.
  4. Arnaout, M.A. (1990) Blood 75:1037.
  5. Postigo, A.A. et al. (1991) J. Exp. Med. 174:1313.
  6. Beyer, M. et al. (2005) Respir. Res. 6:70.
  7. Nicolaou, F. et al. (2003) Blood 101:4033.
  8. Vorup-Jensen, T. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1873.
  9. Bilsland, C.A.G. et al. (1994) J. Immunol. 152:4582.
  10. Pendu, R. et al. (2006) Blood 108:3746.
  11. Sadhu, C. et al. (2007) J. Leukoc. Biol. 81:1395.
  12. Schack, L. et al. (2009) J. Immunol. 182:6943.
  13. Choi, J. et al. (2005) Biochem. Biophys. Res. Commun. 331:557.
  14. Gang, J. et al. (2007) Mol. Cells 24:240.
  15. Vorup-Jensen, T. et al. (2007) J. Biol. Chem. 282:30869.
  16. Vorup-Jensen, T. et al. (2004) Proc. Natl. Acad. Sci. USA 102:1614.
  17. Kishimoto, T.K. et al. (1987) Cell 50:193.

Entrez Gene IDs

3687 (Human)

Gene Symbol

ITGAX

Additional Integrin alpha X beta 2 Products

Product Documents for Recombinant Human Integrin alpha X beta 2 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Integrin alpha X beta 2 Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...